Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2009 |
| End Date: | December 2015 |
A Biologic Correlates Study for "A Phase 2 Single-Arm Study To Assess The Efficacy and Safety Of 48-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once a Week for 3 Weeks of a 4-Week Cycle in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-2 or High Ris
This study is under Molecular and Cellular Characterization of Myelodysplastic Syndromes
(MDS) (eProtocol 15369). The purpose of this proposed study is to analyze existing samples
taken from participants participating in a clinical trial evaluating the efficacy and safety
of investigational agent ON 01910.Na (eProtocol 16214). This study will use existing blood
and marrow samples to determine the rate and duration of objective hematologic and marrow
responses, and duration of progression-free survival in ON01910.Na-treated MDS patients.
This study will use existing blood and marrow samples to determine the rate and duration of
objective hematologic and marrow responses, and duration of progression-free survival in
ON01910.Na-treated MDS patients.
We found this trial at
1
site
Stanford university Hospital and Clinics Throughout our history, we have pioneered medical advances that save...
Click here to add this to my saved trials
